Targeting of cancer energy metabolism.
The main purpose of this review is to update and analyze the effect of several antineoplastic drugs (adriamycin, apoptodilin, casiopeinas, cisplatin, clotrimazole, cyclophosphamide, ditercalinium, NSAIDs, tamoxifen, taxol, 6-mercaptopurine, and alpha-tocopheryl succinate) and energy metabolism inhibitors (2-DOG, gossypol, delocalized lipophilic cations, and uncouplers) on tumor development and progression. The possibility that these antineoplastic drugs currently used in in vitro cancer models, in chemo-therapy, or under study in phase I to III clinical trials induce tumor cellular death by altering also metabolite concentration (i.e., ATP), enzyme activities, and/or energy metabolism fluxes is assessed. It is proposed that the use of energy metabolic therapy, as an alternative or complementary strategy, might be a promising novel approach in the treatment of cancer.
Rodríguez-Enríquez
Sara
S
Departamento de Bioquímica, Instituto Nacional de Cardiología, Tlalpan, Mexico, Mexico. sara.rodriguez@cardiologia.org.mx
Marín-Hernández
Alvaro
A
Gallardo-Pérez
Juan Carlos
JC
Carreño-Fuentes
Liliana
L
Moreno-Sánchez
Rafael
R
D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D002945:Cisplatin / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004734:Energy Metabolism / Q000187:drug effects*; D005260:Female; D006019:Glycolysis / Q000187:drug effects; D006801:Humans; D008297:Male; D009369:Neoplasms / Q000188:drug therapy* / Q000378:metabolism*; D010085:Oxidative Phosphorylation / Q000187:drug effects; D014475:Uncoupling Agents / Q000494:pharmacology
D000970:Antineoplastic Agents; D014475:Uncoupling Agents; D002945:Cisplatin